MARKET

IRWD

IRWD

Ironwood Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.21
+0.10
+0.99%
After Hours: 10.63 +0.42 +4.11% 19:30 03/08 EST
OPEN
10.51
PREV CLOSE
10.11
HIGH
10.71
LOW
10.16
VOLUME
4.63M
TURNOVER
--
52 WEEK HIGH
12.55
52 WEEK LOW
7.99
MARKET CAP
1.64B
P/E (TTM)
15.46
1D
5D
1M
3M
1Y
5Y
Global Irritable Bowel Syndrome (IBS) Treatment Market Outlook, Industry Analysis and Prospect 2020 -2026
Heraldkeepers · 4d ago
Uric Acid Drug Market 2020 Present Scenario and Growth Prospects, Business Standards and Forecast to 2026
Mar 04, 2021 (Market Insight Reports) -- Rise in the incidence and prevalence of gout and other related disorders, increased research and development...
Market Insight Reports · 4d ago
Insider Trends: Ironwood Pharmaceuticals Insider 90-Day Buying Trend Prolonged with Purchase
MT Newswires · 5d ago
Edward Owens Is The Independent Director of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And They Just Picked Up 5.9% More Shares
Potential Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders may wish to note that the Independent Director...
Simply Wall St. · 03/01 11:40
Worldwide Irritable Bowel Syndrome with Constipation Drugs Industry to 2028 - Rising Prevalence of Gastrointestinal Disorders Will Significantly Increase the Demand
Dublin, Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 26, 2021 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome with Constipation Drugs Market...
GlobeNewswire · 02/26 11:19
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences,...
GlobeNewswire · 02/25 21:06
Nonerosive Reflux Disease Treatment Market Segmented Application and Geography Trends, Growth and Forecasts to 2020 - 2027 By Ameco Research
pune, India, Thu, 25 Feb 2021 00:44:24 / Comserve Inc. / -- Nonerosive Reflux Disease Treatment market to help players in achieving a strong market position....
Comserve · 02/25 05:46
Global Constipation Treatment Drug Market Size 2021-2026 With Top Countries Data Industry Growth, Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions Analysis Research Report | With Covid 19 Analysis
Feb 25, 2021 (The Expresswire) -- “Constipation Treatment Drug Market” Report (2021-2026) offers a learned and top to bottom investigation on the current...
The Express Wire · 02/25 05:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IRWD. Analyze the recent business situations of Ironwood Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IRWD stock price target is 11.00 with a high estimate of 13.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 319
Institutional Holdings: 182.84M
% Owned: 113.59%
Shares Outstanding: 160.96M
TypeInstitutionsShares
Increased
68
10.45M
New
66
-964.89K
Decreased
62
10.27M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Non-Executive Chairman/Independent Director
Julie McHugh
President
Thomas McCourt
Chief Executive Officer/Director
Mark Mallon
Chief Financial Officer/Senior Vice President/Chief Accounting Officer
Gina Consylman
Chief Operating Officer/Senior Vice President
Jason Rickard
Senior Vice President/General Counsel
Conor Kilroy
Senior Vice President
Michael Shetzline
Director
Mark Currie
Director
Alexander Denner
Independent Director
Andrew Dreyfus
Independent Director
Jon Duane
Independent Director
Marla Kessler
Independent Director
Catherine Moukheibir
Independent Director
Lawrence Olanoff
Independent Director
Edward Owens
Independent Director
Jay Shepard
No Data
  • All
  • Financials
  • Insiders
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.